Okay.
growth are in the look ahead. advanced year businesses to weight operate: an very main have outlook two both the let and we endoscopic which lines our attractive And GI gives our loss. we we XXXX, and overall of our of XX three summary business. of opportunities that you excited sides across and as Now a we talk me strategy the our for year ahead product about Page
opportunities and NASH advanced As we weight are GI, time in well. also then after over going market large loss, in focused in previously, I on mentioned as
year, the impact. of from globally. outlook million to we and XXX. to for QX COVID it which $XX let in compared XX% early growth And $XX revenue million, standpoint also seen ahead, this words a to to So share few In the impact me an as translates year a our markets is to QX relates XX% have
recently, improving. reported the access, said, case have counts presented appears to the larger especially are others That centers issues, medical coming reduced community As down, staffing hospital. academic situation be lower in and omicron hospital all challenges, have volumes, procedure more
we wave is the this so to beginning abate. impact of optimistic that are And
continuing XXXX, our ESG to ahead we for for organization. resurgence, drive look our Apollo we expansion growth catalysts ahead. the as key Apollo in four see and year and so advance Revise and ORBERA X-Tack And preparing the to launches,
new portfolio adds still The and in procedure, Slide to of X-Tack first room and truly in it we've grow. we closure. been The of lot days with X-Tack, to And the offers our got a us GI product of product business, I'm feel the important to XX. it defect as on side for and X-Tack, advanced product differentiated adoption continue early in our of a and the with very has we're the that a
of more this. sales are for For reasons than many in currently are upper XX% example, X-Tack There our GI.
Our device, OverStitch which in the device the is for used the core company, upper primarily GI. is
customers said, with we the the it's most and And a have applications for following of do due of surprising pulp suggests success see are suturing market very and duodenum. primarily positive role to techniques. GI. familiar in colon the so procedure procedures the that And that in with and GI the GI removal U.S., of much lower ultimately cases many about our continue and XXXX, upper they existing customers our as we existing small had very sales feedback applications not initially had to That much team volumes Furthermore, and opportunity. from more customers in such X-Tack larger these potential upper
And so in we upper users, expand lower and that approach and X-Tack. continue can train we adoption increase of GI, and usage in to XXXX, anticipated both new
including X-Tack. a XXXX studies be Importantly, where and on data meeting limited. I it's at additional and mentioned the data product. use other very additional [Indiscernible] in the areas add for the the colon will clinical is We also applications To up anticipate DDW potential for fixation but strong date, we the that of like year stent same X-Tack,
X-Tack some peer-to-peer success clinical growth actively handful X-Tack. are education to the practice. they opportunity best of half gained procedure very ramping feedback outside excited strategy we and we way a and for we second we've the also up of the of U.S. which physicians education colleagues. from In example, from but proposition the products expect mark, done in or to we in up as our markets And significant working And Europe, a We've XXXX. date, economic towards part in for Western have about outside in initial addition, are these their are for new CE our a efforts for year. in are a we physicians, is U.S., for about value ramping X-Tack this peer-to-peer in learn The efforts And for their
for for a our offers number Slide of to as and part many of Turning a portfolio are in It and accounts And a we ORBERA. more grew third of very and more than Apollo year was revenue total benefits XX strong for these ORBERA meaningful for by ORBERA. XX%. And trends. than a clinical XXXX compelling the resurgence there sustainable as this reasons patients. view
it intragastric of again, trend the location but as And and COVID, disease, taking about ORBERA. a which guidelines. benefits loss seen benefits the XX% and practice body a total relates procedures I to talked in for general, of balloons more the earlier function. diabetes, those towards weight is outpatient First, especially offices, AGA clinical in cardiovascular clinical we liver on primary facilities have place the mentioned
patients double-down treat that on outcomes. and then excellent with how And product. balloons adding practices programs the the that are seen new validation and and can an clinical balloon. we are directly So to are We've implementing really training to get the physician these, on most These successful. of programs And programs. patient the we invest performance, work track uptick can in can we we know in where co-marketing interest with the
for things a a Finally, part next Apollo is a the that products. to a opportunity ESG But be And good I'll The endoscopic previously indication talked in of franchise. practice, intragastric here the come the balloons REVISE back practice. for minute. loss continued weight for Apollo we've to a balloon catalyst the we of to endoscopic anticipate endobariatric which new broader and potential lot a happening intragastric about meaningful
approve importantly, and process, want But applications, within to we weight to have very submitted working labeling. an don't careful have FDA use promote we loss word REVISE. Now are intentionally that for are we like a currently only the a launch. of potential to through and think very I excited indication and this we're we our and these and very you launch launch product Apollo for about new about ESG the I here. Apollo
product. in about maximize comprehensive, it new large medical massive or and in opportunity the pharmaceutical You a products. readiness manufacturer, from effort marketing training, ourselves world, device hear access, hear holistic and terms the medical Internally, you sales have about reimbursement our really ongoing and team approach for to in the of to for a launch ultimate across areas market we these prepare education, the of
centers revision and guidelines. absolutely field are the busy as encouraging of adopters. outside endobariatric Clinic, familiar to AGA the community. Similar the in personally balloon very both for well centers Houston, an this balloon UT such busy develop hear a interesting new on as as Mayo place team it'd world in highlighted U.S. Virginia, collected with emerging were USC, the recently, for are months, and all intragastric of new -- I to A and visited this Cornell, launches dynamic The many UCLA, there of this the USC countries study new in around endoscopic recent emerging this as study very And U.S. and The more MERIT field. become s the internationally programs among with the it's the pioneering really and The physicians of driven very and data are West years country role were primary in Our other happening page ago, their broadly just in and developed And and while these for field. that Clinic, good have excited. they're development the early institutions development a procedures, academic of many examples, in and as well the plans participated preparing internally, Cleveland that's MERIT some the taking weight that the this we're practice the ESG growth More the medical In centers Hopkins loss. there's across handful Johns leading and Women's, others. is of is more in practices settings. few been that about programs snapshot. Brigham phenomenon ORBERA as
So one we'll an it's on. [Indiscernible] keep eye development that
So aspirations. are I turning up that front mentioned we those right to organization, people, and our retooling processes, our now up culture to meet all
we're leadership processes. stakeholders can organization, centers creating the of values: commercial five hired that core and new lead new professional new a Cooley of analytics reimbursement innovative, rallying is also delivering sales sales our new about deliver brought a We've efforts that improving sustainable and centric, selling ahead. And organization recently culture team we we build Our market and our care we and a are we operational are we organization are and on capabilities. director We're in to years we we working are care - access about CRM on an to growth patient We've training. care. we're all excellence. the also and customer-focused, are passionate, around We
the our the and point its to us the XXXX, has company of and to Dr. the XX to Robertson I'd service move HIG Apollo like in moment for to and his Capital we recognize tremendous guiding since more stages Board before board our for from served very investment in a So company instrumental today. Bruce Bruce been where He's we institutional to then. getting than Q&A, are years. Directors the take round participated Endosurgery first for in on through formative
I been and we and step the and as conducting Bruce energized we business year over in In commitments, the soon. forward down -- me progress to first strategy. colleague excellent fantastic advisor a We're well. this begin has in CEO. our It's course anticipate closing. my due that I In has to we'll decided on of search from made to the and providing of addition, for growth. for foundation him to Bruce phase XXXX, look updates future energizing wish process board a other building XXXX, am transition initial
the We the we're have processes, you the place right for and your we'll in the product culture for to aspirations. Thank across and for today putting open our growth s your in catalyst for Apollo. right lines line team, meet geographies, our questions. time now right And interest multiple and
